TOPAMAX (topiramate) by Johnson & Johnson is cytochrome p450 3a4 inducers [moa]. First approved in 1998.
Drug data last refreshed 44m ago · AI intelligence enriched 1w ago
TOPAMAX (topiramate) is an oral small-molecule anticonvulsant approved in 1998 that works as a cytochrome P450 3A4 inducer. While originally developed for seizure disorders, it has been widely used off-label for migraine prophylaxis, weight management, and psychiatric conditions. The drug's multiple mechanisms of action and broad off-label adoption have made it a cornerstone therapy across multiple therapeutic areas.
As LOE approaches, the brand team is likely contracting; careers here focus on maximizing remaining exclusivity and preparing for generic competition rather than growth initiatives.
Cytochrome P450 3A4 Inducers
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users
Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine
Worked on TOPAMAX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TOPAMAX offers limited growth trajectory given its LOE-approaching status and declining job postings, making it a consolidation rather than expansion opportunity. Career progression here emphasizes portfolio defense, generic transition management, and off-label engagement rather than innovation or launch activities.